Hepatotoxicity Due To Mushroom Poisoning: A Case Report

Baniasad N¹, Oghabian Z²*, Mehrpour O³

¹ Department of Internal Medical, Gastroenterologist, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran
² Department of Clinical Toxicology, Forensic Medicine and Clinical Toxicologist, Kerman University of Medical Sciences, Kerman, Iran
³ Department of Clinical Toxicology, Birjand University of Medical Sciences, Birjand, Iran

ABSTRACT

Article Type: Case Report

Article History:
Received: 16 Aug 2013
Revised: 16 Sep 2013
Accepted: 1 Feb 2014

Keywords:
Amanita
Mushroom Poisoning
High-Dose Penicillin
N-AcetylCysteine
Silymarin

Background: Although the majority of mushroom ingestions are benign, some result in significant toxicity and death. Of greatest concern is the hepatotoxic amatoxin-containing mushroom, which may be fatal even small ingestions. Identification of amatoxin poisoning can prove to be difficult due to delay in onset of symptoms and difficulty with identification of mushrooms.

Case Report: We present one case of mushroom ingestion in Kerman, province what according to clinical course and laboratory finding, we believe to be an amanita species, treated with multiple dose of activated charcoal, N-acetylcysteine, high-dose penicillin and liver GOL (silymarin).

Conclusion: We present the successful treatment a patient who ingested hepato-toxicity induced mushrooms, further, this case is evidence of a mushroom variety responsible for toxicity never previously implicated in the southeastern Iran.

Implication for health policy/practice/research/medical education:
Hepatotoxicity Due To Mushroom Poisoning


1. Introduction:
Of the possibly 10000 species of mushrooms world wide, only so to 100 are known to be toxic (1). Although the majority of mushrooms ingestions are benign, some result in significant toxicity and death (2). Analysis of exposures reported to poison control centers in the United States indicates that the precise species of mushrooms is identified in only 3.4% of all exposures (3). The cyclopeptide-containing mushrooms are responsible for more than 90% of all deaths due to mushrooms poisoning in the western world (1). Of greatest concern are the hepatotoxic amatoxin-containing mushrooms, which maybe fatal after even small ingestions. Amatoxin poisoning may be difficult to diagnose due to delayed onset of...
symptoms (2). we present successful treatment of one case of mushroom poisoning that according to clinical course and laboratory finding, suggested that must be amatoxin containing mushroom.

2. Case Report:
A 66 years old woman, who live in region near Kerman city and without any past medical histories presented to Kerman Afzalipour hospital with complaints of nausea vomiting, sever watery diarrhea, weakness and moderate abdominal pain after ingestion of mushrooms she reportedly picked the mushrooms which was growing along the river in her home. She fried the mushrooms and ingested it with egg. The mushroom was described as coupled and having white colored cap. She ate the mushroom at approximately 9:00 PM.

The following day at approximately 7:00 am (10h later), she started developing nausea vomiting, sever watery diarrhea and RUQ pain.

she presented to Kerman Afzalipour hospital at approximately 10:00 pm ,the patient’s initial vital signs were, temperature 36.6°C orally pulse 110 beats/min, blood pressure 120/80mm/Hg respiratory rate 26 breaths/min and oxygen saturation 95% on ambient air.

her initial aspartate aminotransferase (AST) was 97 IU/L (normal range 5-40 IU/L), alanine aminotransferase (ALT) was 56 IU/L (normal range 5-40 IU/L), and international normalized ratio (INR) was 1.5 (normal range 0.8-1.2), in the complete blood cell count leukocytosis and in ABG a mild metabolic acidosis was noted. On physical examination, the patient had right upper quadrant tenderness to palpation. Neither had guarding nor rebound. The rest of physical examination was otherwise normal. Fluid and electrolyte resuscitation was performed and 12h later the patient had no gastrointestinal complain except RUQ pain. According to clinical course and laboratory data we identified probably Amatoxin-containing mushrooms poisoning and the following treatment regimen was started: 60gr activated charcoal (AC) and then multiple dose activated charcoal (MDAC) with 30gr (0.5gr/kg) (AC) continued every 4 hours for 24h.

N-Acetylcysteine (NAC) at 150 mg/kg loading dose intravenous (i.v.) and then the NAC continued at 50mg/kg dose over 9h, followed by 100mg/kg over 16h. NAC continued in following day at 150 mg/kg 1 day dose until decreasing liver aminotransferase.

High–dose penicillin G (10000000 units/kg/day/iv) for 48h and was continued at 5000000 units/kg/day/IV, until decreasing liver aminotransferase (day 5). Liver Gol (70 mg/bid/dose) and vit. K (10 mg/day) were continued orally during hospitalization. Abdominal sonography was normal. the patient’s peak AST was 753 IU/L and ALT was 1326 IU/L approximately 36-48h after ingestion (table 1, fig.1) the patient’s transaminase levels eventually began trending down ward approximately 72h after mushrooms ingestion.

the patient was discharged on hospital day 6 with AST 80 IU/L and ALT 398IU/L. seven day follow up (14-day after ingestion revealed AST 20 IU/L and ALT 57 IU/L.

A follow up telephone conversation 1 month after discharge revealed that the patient was asymptomatic, with no evidence of ongoing toxicity or sequelae.

3. Discussion:
Amatoxin poisoning maybe is difficult to diagnose due to the delayed onset of symptoms (2). Amatoxin-containing mushrooms cause >95% of mushrooms–ingestion deaths (4). In a retrospective study of mushrooms poisoning in Iran, from 1992 to 2002, of the 72421 poisoning cases admitted to Loghman-Hakim hospital poison center 37
Table 1: Laboratory Findings

<table>
<thead>
<tr>
<th>Laboratory tests</th>
<th>12h</th>
<th>24h</th>
<th>36h</th>
<th>Day2</th>
<th>Day3</th>
<th>Day4</th>
<th>Day5</th>
<th>Day6</th>
<th>Day14</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC (K/µL)</td>
<td>15.200</td>
<td>15.600</td>
<td>13.800</td>
<td>-</td>
<td>6.300</td>
<td>7000</td>
<td>-</td>
<td>7.700</td>
<td>-</td>
</tr>
<tr>
<td>Hb (g/dl)</td>
<td>14.9</td>
<td>13.6</td>
<td>13.3</td>
<td>-</td>
<td>12</td>
<td>12.4</td>
<td>-</td>
<td>11.1</td>
<td>-</td>
</tr>
<tr>
<td>Plt (k/µl)</td>
<td>470</td>
<td>455</td>
<td>316</td>
<td>-</td>
<td>281</td>
<td>289</td>
<td>-</td>
<td>309</td>
<td>-</td>
</tr>
<tr>
<td>Ast (IU/L)</td>
<td>97</td>
<td>252</td>
<td>753</td>
<td>600</td>
<td>224</td>
<td>115</td>
<td>58</td>
<td>80</td>
<td>20</td>
</tr>
<tr>
<td>Alt (IU/L)</td>
<td>56</td>
<td>203</td>
<td>1246</td>
<td>1326</td>
<td>1132</td>
<td>892</td>
<td>489</td>
<td>398</td>
<td>57</td>
</tr>
<tr>
<td>Bili (total, Mg/dl)</td>
<td>0.9</td>
<td>0.5</td>
<td>0.8</td>
<td>0.7</td>
<td>0.7</td>
<td>0.5</td>
<td>0.4</td>
<td>0.6</td>
<td>0.3</td>
</tr>
<tr>
<td>Bilirubin (Direct, Mg/dl)</td>
<td>0.3</td>
<td>0.2</td>
<td>0.2</td>
<td>0.3</td>
<td>0.3</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>PT (second)</td>
<td>16.5</td>
<td>14.5</td>
<td>21.5</td>
<td>&gt;38</td>
<td>14.1</td>
<td>17.5</td>
<td>13</td>
<td>14.8</td>
<td>12</td>
</tr>
<tr>
<td>PTT (second)</td>
<td>38</td>
<td>31</td>
<td>52</td>
<td>&gt;100</td>
<td>43</td>
<td>34</td>
<td>30</td>
<td>4.1</td>
<td>35</td>
</tr>
<tr>
<td>INR</td>
<td>1.5</td>
<td>1.2</td>
<td>2.3</td>
<td>&gt;5.6</td>
<td>1.1</td>
<td>1.6</td>
<td>1</td>
<td>1.2</td>
<td>1</td>
</tr>
<tr>
<td>BUN</td>
<td>78</td>
<td>83</td>
<td>45</td>
<td>22</td>
<td>40</td>
<td>15</td>
<td>13</td>
<td>23</td>
<td>20</td>
</tr>
<tr>
<td>Cr</td>
<td>1.8</td>
<td>1.8</td>
<td>1.1</td>
<td>1</td>
<td>1</td>
<td>1.1</td>
<td>1.1</td>
<td>1.1</td>
<td>0.8</td>
</tr>
<tr>
<td>PH</td>
<td>7.31</td>
<td>7.33</td>
<td>7.38</td>
<td>7.43</td>
<td>7.43</td>
<td>7.42</td>
<td>7.38</td>
<td>7.44</td>
<td>7.43</td>
</tr>
<tr>
<td>HCO3</td>
<td>15.7</td>
<td>17.3</td>
<td>17.2</td>
<td>16.8</td>
<td>21.2</td>
<td>24.0</td>
<td>22.6</td>
<td>22.1</td>
<td>24</td>
</tr>
<tr>
<td>Bs</td>
<td>144</td>
<td>139</td>
<td>-</td>
<td>100</td>
<td>-</td>
<td>114</td>
<td>-</td>
<td>117</td>
<td>100</td>
</tr>
<tr>
<td>Alb</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3.4</td>
<td>-</td>
<td>-</td>
<td>2.9</td>
<td>-</td>
<td>3.7</td>
</tr>
<tr>
<td>Total protein</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6.5</td>
<td>-</td>
<td>-</td>
<td>5.4</td>
<td>-</td>
<td>6.4</td>
</tr>
</tbody>
</table>

For a patient with a history of toxic mushrooms ingestion, the clinical picture may help determine to which group the mushroom belonged, pending definitive identification. In majority of cases, the true identity of offending mushroom is unknown (1).
Hepatotoxicity Due To Mushroom Poisoning: A Case Report

4. Diagnosis:
The diagnosis of cyclopeptide mushroom poisoning is made largely from a positive history of ingestion coupled with suggestive physical findings (e.g., acute gastroenteritis, and toxic hepatitis). Optimally, the mushroom (obtained from meal leftovers or from visiting the site of foraging) could be identified by an experienced mycologist, but this is rarely possible. Circulating amatoxins can be detected for hours after ingestion (13).

Most of the ingested α-amanitin is excreted renally and urine levels tend to be higher than serum levels, although amatoxins can be detected by very sensitive radio immunoassay or high–pressure liquid chromatographic methods these assays are not usually clinically available (1).

Management options for patients with ingestions or toxicity are varied and controversial.

General after stabilization and airway management, intravenous fluids and antiemetics are likely required because most patients present with nausea and vomiting. Patient who present with vomiting within 6h are more likely to have ingested a more benign mushroom, however, it can never be assumed that patients presenting with nausea and vomiting before 6h have not ingested a lethal mushroom, because co-ingestion of both lethal and non-lethal mushrooms can occur (2).

Multiple dose activated charcoals (MDAC): patients may be administered AC as amatoxins are enterohepatically circulated.

Patients presenting early in the course of illness who have not yet developed hepatic injury may also benefit from repeat dose AC (2).

N-acetylcysteine (NAC) .NAC has been advocated on the theoretical basis that is reduces radical-induced injury and restores redox capacity in injured cells (2).

It may also be beneficial in preventing liver injury via free radical or oxygen–

![Fig. 1. AST and ALT results.](image)

(namely, the GI tract and liver) are most sensitive to this poisoning (1).

Circulating amatoxins in not metabolized but excreted by the biliary system and the kidneys. Enterohepatic recirculation and biliary excretion of amatoxins are significant.

The cyclopeptides are not denatured by boiling and hence cooking deadly amanita mushrooms dose not render them non-toxic. It is estimated that approximately 0.1mg/kg of oral mushroom may be lethal to an adult (12).

**Clinical presentation:**

The classic clinical presentation of amanita poisoning can be divided into three stages .patient do not have GI symptoms for at least 6 hours after ingestion , and then they develop colicky abdominal pain ,vomiting and severe diarrhea (stage1).

The onset of symptoms may occur from 6 to 24 hours after ingestion .the diarrhea may contain blood and mucus and may be so severe that it has been termed cholera-like.

Even without treatment, patients may apparently recover (stage 2).

Although their hepatic enzyme levels may be raising .two to 4 days after ingestion, patients may suffer fulminant hepatitis, cardiac and renal failure (stage 3).

Pancreatitidis disseminated intravascular coagulation, convulsions and death may then occur in the subsequent 2 to 4 days (1).
scavenging capabilities after ingestion (14).

A report of 11 patients with apparent poisonous A phalloides poisoning treated with infusion of N-acetylcysteine (NAC) reported survival in all, with only one patient requiring liver transplantation (15). Also, due to NAC’s benign side effect profile, the possible benefits are generally believed to justify administration (15).

**Penicillin**

Penicillin G may have a time- and dose-dependent protective effect by either displacing a-amanitin from albumin, blocking its uptake from hepatocytes, binding to RNA polymerase (14). Penicillin in doses ranging from 300000 to 1000000 units/kg/day is thought to inhibit amatoxin uptake by hepatocytes (17). High-dose penicillin was found protective in retrospective animal and human studies. It should be used with caution due to the rare risk of anaphylaxis (18).

**Silymarin**

In Iran, it is available in form of liver Gol tablet. Silymarin is the most frequently used complementary and alternative medicine for liver disease in the United States (19). It is proposed to be hepato protective by promoting hepatocyte growth, and inhibiting hepatic oxidation and inflammation (19). One large retrospective study involving 2108 patients poisoned with amatoxin–containing mushrooms concluded that silybin monotherapy was an effective treatment modality (20). Clinical trial amounts of silymarin range 420-480 mg per day (21).

**Cimetidine**

Cimetidine has been advocated for the treatment of amatoxin–containing mushrooms. The rationale for the use of cimetidine was the similarity in clinical course and history (centrilobular necrosis) of amanita poisoning with acetaminophen (APAP) hepatotoxicity (22). Relative to historical controls, there was a decrease in mortality (not statistically significant) and a more rapid return to normal transaminase levels, implying a decrease in ongoing hepatocellular injury in human studies (23). No prospective trials however, have evaluated the use of cimetidine (2).

**Hemodialysis**

Hemodialysis has never been proven beneficial in case of amanita poisoning. For example, no amatoxin clearance was demonstrated 23 h post ingestion of Amanita phalloides in 2 patients (24). Plasmapheresis may be of some benefit (25). However liver transplant may eventually be necessary in the setting of sever hepatotoxicity, encephalopathy, and hemodynamic compromise. If mushrooms can be presumptively identified as containing am toxin, then the information can be used to justify early aggressive patient outcome and mortality, which may have helped in the successful outcome of our patient.

5. Conclusion:

We report the successful treatment of a mushroom poisoned patient in Kerman (which according to clinical course and laboratory finding, suggested that must be amatoxin–containing mushroom) with NAC, high-dose penicillin, MDAC, liver Gol.

Finally, this is the first time Amanita-containing mushrooms poisoning in Kerman.

**References**


